TY - JOUR
T1 - Synergistic antitumor effect of interferon-β with gemcitabine in interferon-α-non-responsive pancreatic cancer cells
AU - Tomimaru, Yoshito
AU - Eguchi, Hidetoshi
AU - Wada, Hiroshi
AU - Tomokuni, Akira
AU - Kobayashi, Shogo
AU - Marubashi, Shigeru
AU - Takeda, Yutaka
AU - Tanemura, Masahiro
AU - Umeshita, Koji
AU - Mori, Masaki
AU - Doki, Yuichiro
AU - Nagano, Hiroaki
PY - 2011/5
Y1 - 2011/5
N2 - Interferon (IFN)-β is reported to have more potent antitumor effects than IFN-α. The aim of this study was to compare the synergistic antitumor activity of both IFNs when combined with gemcitabine on cultured pancreatic cancer cells expressing various levels of IFN receptor. The growth-inhibitory effects of IFN-α and IFN-β in combination with gemcitabine on three human pancreatic cancer cell lines (BxPC-3, MIAPaCa-2, Panc-1) were evaluated by MTT assay and isobolographic analysis. We also correlated their growth-inhibitory effects with the expression status of type I IFN receptor type 2 (IFNAR2). Western blot analysis indicated strong expression of IFNAR2 in BxPC-3 and MIAPaCa-2, but weak expression in Panc-1. The growth-inhibitory effect of gemcitabine was enhanced synergistically by IFN-α in BxPC-3 and MIAPaCa-2, but not in Panc-1. IFN-β exhibited more potent synergistic growth-inhibitory effects with gemcitabine in BxPC-3 and MIAPaCa-2 compared to IFN-α, and also synergistic enhancement in Panc-1. In conclusion, our results indicated that the growth-inhibitory effect of IFN-β with gemcitabine was synergistic not only in pancreatic cancer cells with strong expression of IFNAR2, but also in those with weak expression of IFNAR2.
AB - Interferon (IFN)-β is reported to have more potent antitumor effects than IFN-α. The aim of this study was to compare the synergistic antitumor activity of both IFNs when combined with gemcitabine on cultured pancreatic cancer cells expressing various levels of IFN receptor. The growth-inhibitory effects of IFN-α and IFN-β in combination with gemcitabine on three human pancreatic cancer cell lines (BxPC-3, MIAPaCa-2, Panc-1) were evaluated by MTT assay and isobolographic analysis. We also correlated their growth-inhibitory effects with the expression status of type I IFN receptor type 2 (IFNAR2). Western blot analysis indicated strong expression of IFNAR2 in BxPC-3 and MIAPaCa-2, but weak expression in Panc-1. The growth-inhibitory effect of gemcitabine was enhanced synergistically by IFN-α in BxPC-3 and MIAPaCa-2, but not in Panc-1. IFN-β exhibited more potent synergistic growth-inhibitory effects with gemcitabine in BxPC-3 and MIAPaCa-2 compared to IFN-α, and also synergistic enhancement in Panc-1. In conclusion, our results indicated that the growth-inhibitory effect of IFN-β with gemcitabine was synergistic not only in pancreatic cancer cells with strong expression of IFNAR2, but also in those with weak expression of IFNAR2.
UR - http://www.scopus.com/inward/record.url?scp=79955048175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955048175&partnerID=8YFLogxK
U2 - 10.3892/ijo.2011.954
DO - 10.3892/ijo.2011.954
M3 - Article
C2 - 21347515
AN - SCOPUS:79955048175
SN - 1019-6439
VL - 38
SP - 1237
EP - 1243
JO - International journal of oncology
JF - International journal of oncology
IS - 5
ER -
